IQVIA (IQV) is moving higher as the market digests the company’s first-quarter 2026 earnings update released May 5, 2026. The key catalyst is a profitability outlook lift for the full year, alongside results that came in ahead of expectations and signals of resilient demand across its clinical research and healthcare analytics footprint. (marketbeat.com)

IQVIA reported Q1 2026 revenue of about $4.15 billion, up roughly 8.4% year over year, and raised its FY2026 adjusted diluted EPS guidance range to $12.65–$12.95. The company also reaffirmed full-year revenue guidance of $17.15–$17.35 billion, helping reinforce confidence that near-term execution can hold despite a choppy backdrop for healthcare services spending. (marketbeat.com)

Beyond the earnings beat and higher EPS outlook, investors are focusing on cash generation and capital return: IQVIA repurchased roughly $552 million of stock during the quarter, a supportive technical tailwind while the company works through a volatile 2026 tape for large-cap healthcare and services names. The combination of raised profitability guidance plus buybacks is underpinning the post-results re-rating. (chartmill.com)

Traders will be watching whether IQVIA can sustain mid-to-high single-digit revenue growth while protecting margins as the year progresses, since the current rally is built on the idea that earnings power is improving even if the top-line environment remains uneven. Any incremental changes to bookings, backlog trends, or additional guidance updates over the next few weeks could determine whether today’s move extends or fades. (investing.com)